Ad www.ProStocks.com
FREE Account Opening + No Clearing Fees + Rs 999 API Access
|
|
Supriya Lifescience is engaged in the manufacturing of Active pharmaceutical ingredients (APIs). As of March 31, 2021, the company produces 38 APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and anti-allergic. The company has been the largest exporter of Chlorpheniramine Maleate and Ketamine Hydrochloride from India between Fiscal 2017 and 2021. The company is also one of the largest exporters of Salbutamol Sulphate from India in FY 2021 in terms of volume.
In Fiscal 2021, the company's products were exported to 86 countries to 1,296 customers including 346 distributors. The company has API business in Europe, Latin America, Asia, and North America.
Supriya Lifescience has a modern manufacturing facility in Maharashtra spread across 23,806 sq. mts, having a reactor capacity of 547 KL/ day including 7 clean rooms. The company has also acquired a plot of land, admeasuring 12,551 sq. mt, near the present manufacturing facility, to expand its manufacturing infrastructure. The company's manufacturing facility has received approvals from USFDA, EDQM TGA-Australia, KFDA-Korea, PMDA Japan, NMPA (previously known as SFDA)- China, Health Canada, in relation to API products being exported to the relevant jurisdictions by the company.
Satish Waman Wagh is the company promoter.
| Particulars | For the year/period ended (₹ in Millions) | ||||
|---|---|---|---|---|---|
| 30-Sep-21 | 31-Mar-21 | 31-Mar-20 | 31-Mar-19 | ||
| Total Assets | 5,041.02 | 4,458.24 | 3,364.01 | 2,530.52 | |
| Total Revenue | 2,300.61 | 3,962.21 | 3,227.13 | 2,858.62 | |
| Profit After Tax | 659.59 | 1,238.28 | 733.74 | 394.24 | |
| IPO Opening Date | Dec 16, 2021 |
| IPO Closing Date | Dec 20, 2021 |
| Issue Type | Book Built Issue IPO |
| Face Value | ₹2 per equity share |
| IPO Price | ₹265 to ₹274 per equity share |
| Market Lot | 54 Shares |
| Min Order Quantity | 54 Shares |
| Listing At | BSE, NSE |
| Issue Size | [.] Eq Shares of ₹2 (aggregating up to ₹700.00 Cr) |
| Fresh Issue | [.] Eq Shares of ₹2 (aggregating up to ₹200.00 Cr) |
| Offer for Sale | [.] Eq Shares of ₹2 (aggregating up to ₹500.00 Cr) |
| QIB Shares Offered | Not less than 75% of the Offer |
| Retail Shares Offered | Not more than 10% of the Offer |
| NII (HNI) Shares Offered | Not more than 15% of the Offer |
The Supriya Lifescience IPO open date is Dec 16, 2021, and the close date is Dec 20, 2021. The issue may list on Dec 28, 2021.
| IPO Open Date | Dec 16, 2021 |
| IPO Close Date | Dec 20, 2021 |
| Basis of Allotment Date | Dec 23, 2021 |
| Initiation of Refunds | Dec 24, 2021 |
| Credit of Shares to Demat Account | Dec 27, 2021 |
| IPO Listing Date | Dec 28, 2021 |
The Supriya Lifescience IPO market lot size is 54 shares. A retail-individual investor can apply for up to 13 lots (702 shares or ₹192,348).
| Application | Lots | Shares | Amount (Cut-off) |
|---|---|---|---|
| Minimum | 1 | 54 | ₹14,796 |
| Maximum | 13 | 702 | ₹192,348 |
| Pre Issue Share Holding | 99.98% |
| Post Issue Share Holding | 68.24% |
SLL has been making strides with higher top and bottom lines year after year and exporting over 75% of products to more than 86 countries. Based on financial parameters, the issue is attractively priced leaving something on the table across the board. The issue is worth considering for short to long term rewards. Read detail review...
The Supriya Lifescience IPO is subscribed 71.51 times on Dec 20, 2021 7:52:00 PM. The public issue subscribed 56.01 times in the retail category, 31.83 times in the QIB category, and 161.22 times in the NII category. Check Day by Day Subscription Details (Live Status)
| Category | Subscription (times) |
|---|---|
| QIB | 31.83 |
| NII | 161.22 |
| Retail | 56.01 |
| Total | 71.51 |
| Listing Date | Tuesday, December 28, 2021 |
| BSE Script Code | 543434 |
| NSE Symbol | SUPRIYA |
| Listing In | B Group of Securities |
| ISIN | INE07RO01027 |
| IPO Price | ₹274 per equity share |
| Face Value | ₹2 per equity share |
|
|
|
Supriya Lifescience Limited
207/208, Udyog Bhavan,
Sonawala Road, Goregaon,
East, Mumbai – 400063, Maharashtra, India
Phone: +91-22-40332727
Email: cs@supriyalifescience.com
Website: https://supriyalifescience.com/
Link Intime India Private Ltd
Phone: +91-22-4918 6270
Email: supriyalife.ipo@linkintime.co.in
Website: https://linkintime.co.in/
Supriya Lifescience IPO is a main-board IPO of [.] equity shares of the face value of ₹2 aggregating up to ₹700.00 Crores. The issue is priced at ₹265 to ₹274 per equity share. The minimum order quantity is 54 Shares.
The IPO opens on Dec 16, 2021, and closes on Dec 20, 2021.
Link Intime India Private Ltd is the registrar for the IPO. The shares are proposed to be listed on BSE, NSE.
Zerodha customers can apply online in Supriya Lifescience IPO using UPI as a payment gateway. Zerodha customers can apply in Supriya Lifescience IPO by login into Zerodha Console (back office) and submitting an IPO application form.
Steps to apply in Supriya Lifescience IPO through Zerodha
Visit Zerodha IPO Application Process Review for more detail.
The Supriya Lifescience IPO opens on Dec 16, 2021 and closes on Dec 20, 2021.
Supriya Lifescience IPO lot size is 54 Shares and the minimum order quantity is 54 Shares.
You can apply in Supriya Lifescience IPO online using either UPI or ASBA as payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO application is offered by brokers who don't offer banking services. Read more detail about apply IPO online through Zerodha, Upstox, 5Paisa, Edelweiss, ICICI Bank, HDFC Bank and SBI Bank.
The finalization of Basis of Allotment for Supriya Lifescience IPO will be done on Dec 23, 2021, and the allotted shares will be credited to your demat account by Dec 27, 2021. Check the Supriya Lifescience IPO allotment status.
Useful Articles
